Changes in Hong Kong stocks | Yaojie Ankang-B (02617) rose more than 9% in early trading and was previously approved by the State Drug Administration for inclusion in the list of priority review varieties

The Zhitong Finance App learned that Yaojie Ankang-B (02617) rose more than 9% in early trading. As of press release, it had risen 4.9% to HK$179.7, with a turnover of HK$779.64 million.

According to the news, Yaojieankang-B previously announced that tengotinib tablets have been approved by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) to be included in the list of priority review varieties. The proposed indications are: for the treatment of adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received at least one systematic treatment and treatment with FGFR inhibitors in the past. Previously, tengotinib was recognized by the NMPA as a breakthrough treatment for cholangiocarcinoma.

Furthermore, recently, Yaojie Ankang-B announced that the company's core product, tengotinib, an exploratory phase 2 clinical results for cholangiocarcinoma carried out in the US were published in “The Lancet, Gastroenterology, and Hepatology” (influencing factor 38.6). In this phase 2, open-label, multicenter study (NCT04919642), eligible cholangiocarcinoma patients included patients with FGFR2 fusion and primary or acquired resistance to FGFR inhibitors, or patients with other FGFR gene changes, and FGFR wild-type patients. Tengotinib overcame acquired resistance to FGFR inhibitors in patients with FGFR2 fusion positive cholangiocarcinoma and showed antitumor activity in other cholangiocarcinoma patients with altered FGFR genes.